Coherus Oncology, Inc. (CHRS) Stock Overview
NASDAQ · Healthcare · Biotechnology
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation…
Source: Yahoo Finance
Sector & Industry
Coherus Oncology, Inc. operates in the Healthcare sector, within the Biotechnology industry group. It is listed on the NASDAQ exchange.
Coherus Oncology, Inc. at a Glance
| Company | Coherus Oncology, Inc. |
| Ticker | CHRS |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $1.42 |
| Market cap | $219.39M |
| P/E ratio (trailing) | — |
| EPS (trailing) | -$1.24 |
| 52-week high | $2.62 |
| 52-week low | $1.09 |
| Dividend yield | — |
| Ex-dividend date | — |
| Beta | 0.94 |
| Return on equity (ROE) | -178.39% |
| Debt-to-equity | 89.05% |
| Average volume | 976,166 |
| Shares outstanding | 154.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 144 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Frequently Asked Questions
- What is Coherus Oncology, Inc.'s current P/E ratio?
- Coherus Oncology, Inc. (CHRS) has a trailing P/E ratio of — as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Coherus Oncology, Inc.'s market capitalisation?
- Coherus Oncology, Inc.'s market cap is $219.39M based on our latest snapshot. See how it ranks by market cap →
- What is CHRS's 52-week range?
- Over the past 52 weeks, CHRS has traded between $1.09 and $2.62. What does the 52-week range mean? →
- How volatile is Coherus Oncology, Inc. compared to the market?
- Coherus Oncology, Inc. has a beta of 0.94, meaning it has historically moved less than the broader market. What does beta measure? →
- Does Coherus Oncology, Inc. pay a dividend?
- Coherus Oncology, Inc. does not currently pay a dividend according to our latest data.
- What exchange is CHRS listed on?
- CHRS is listed on the NASDAQ. Browse all NASDAQ-listed stocks →
- What sector is Coherus Oncology, Inc. in?
- Coherus Oncology, Inc. is classified in the Healthcare sector. Compare with Healthcare peers →
Need to convert currencies or units alongside this data? Our quick conversion tools are always on hand.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Philip Fisher on what makes a business worth owning for the long term.
Check Price →Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →